gene	protein	cdna	transcript	disease	allele_fraction	func_class	class	editor	strand	pam	tier	bystander	correction	pmid_pmc
PIK3CA	E109del	c.325_327delGAA	NM_006218.3	LM	LEC line	GoF	indel	-	-	-	indel	-	prime editing / gene replacement	PMC6037383
PIK3CA	E110del	c.328_330del	NM_006218.3	LM	1.06-2.70%	GoF	indel	-	-	-	indel	-	prime editing / gene replacement	PMC8194016
PIK3CA	R88Q	c.263G>A	NM_006218.3	LM	0.52%	GoF	transition	ABE	antisense	NGG	clean-BE	silent;silent	base editing (clean)	PMC11184491
PIK3CA	R88Q	c.263G>A	NM_006218.3	GLA	1.3%	GoF	transition	ABE	antisense	NGG	clean-BE	silent;silent	base editing (clean)	PMC11184491
PIK3CA	N345K	c.1035T>A	NM_006218.3	LM	<=1.4%	GoF	transversion	-	-	-	transversion	-	prime editing	PMC8972000
PIK3CA	C420R	c.1258T>C	NM_006218.3	LM	LEC line	GoF	transition	CBE	coding	NGG	BE-with-bystanders	H419Y;silent	base editing (bystander)	PMC6037383; PMC4498659
PIK3CA	E542K	c.1624G>A	NM_006218.3	LM	0.5-23%	GoF	transition	ABE	coding	NGG	clean-BE	-	base editing (clean)	PMC8194016; PMC6363432
PIK3CA	E542K	c.1624G>A	NM_006218.3	GLA	0.5-23%	GoF	transition	ABE	coding	NGG	clean-BE	-	base editing (clean)	PMC8194016; PMC6363432
PIK3CA	E545A	c.1634A>C	NM_006218.3	LM	LEC line	GoF	transversion	-	-	-	transversion	-	prime editing	PMC4498659
PIK3CA	E545G	c.1634A>G	NM_006218.3	LM	6.55-10.01%	GoF	transition	CBE	antisense	NGG	BE-with-bystanders	G545R	base editing (bystander)	PMC8194016
PIK3CA	E545K	c.1633G>A	NM_006218.3	LM	0.5-23%	GoF	transition	ABE	coding	none	no-PAM	-	prime editing (no PAM)	PMC8972000
PIK3CA	E545K	c.1633G>A	NM_006218.3	KLA	11.3%	GoF	transition	ABE	coding	none	no-PAM	-	prime editing (no PAM)	PMC11184491
PIK3CA	Q546K	c.1636C>A	NM_006218.3	LM	1.1-23%	GoF	transversion	-	-	-	transversion	-	prime editing	PMC6037383
PIK3CA	Q546K	c.1636C>A	NM_006218.3	GLA	1.1-23%	GoF	transversion	-	-	-	transversion	-	prime editing	PMC6363432
PIK3CA	Q546R	c.1637A>G	NM_006218.3	LM	2.16-3.96%	GoF	transition	CBE	antisense	NG	clean-BE	silent;silent	base editing (clean)	PMC8194016
PIK3CA	M1043I	c.3129G>A	NM_006218.3	CCLA	5.6%	GoF	transition	ABE	antisense	NGG	BE-with-bystanders	M1043V;N1044D;N1044S	prime editing	PMC11184491
PIK3CA	H1047L	c.3140A>T	NM_006218.3	LM	2.47-2.52%	GoF	transversion	-	-	-	transversion	-	prime editing	PMC8194016
PIK3CA	H1047L	c.3140A>T	NM_006218.3	GLA	2.47-2.52%	GoF	transversion	-	-	-	transversion	-	prime editing	PMC6363432
PIK3CA	H1047L	c.3140A>T	NM_006218.3	CCLA	0.15-1.25%	GoF	transversion	-	-	-	transversion	-	prime editing	PMC11184491
PIK3CA	H1047R	c.3140A>G	NM_006218.3	LM	3.9-11%	GoF	transition	CBE	antisense	NG	clean-BE	-	base editing (clean)	PMC8972000
PIK3CA	H1047R	c.3140A>G	NM_006218.3	GLA	3.9-11%	GoF	transition	CBE	antisense	NG	clean-BE	-	base editing (clean)	PMC6363432
PIK3CA	H1047R	c.3140A>G	NM_006218.3	KLA	0.41%	GoF	transition	CBE	antisense	NG	clean-BE	-	base editing (clean)	PMC11184491
PIK3CA	H1047R	c.3140A>G	NM_006218.3	CCLA	0.88%	GoF	transition	CBE	antisense	NG	clean-BE	-	base editing (clean)	PMC11184491
PIK3CD	L666P	c.1997T>C	NM_005026.4	LM	2-3%	GoF	transition	CBE	coding	NG	clean-BE	silent;silent	base editing (clean)	PMC8106842
NRAS	Q61R	c.182A>G	NM_002524.4	KLA	0.54-28%	GoF	transition	CBE	antisense	NG	BE-with-bystanders	E62K	base editing (bystander)	PMC6565516; PMC11184491
NRAS	Q61R	c.182A>G	NM_002524.4	GLA	30%	GoF	transition	CBE	antisense	NG	BE-with-bystanders	E62K	base editing (bystander)	PMID29397482
NRAS	Q61K	c.181C>A	NM_002524.4	KLA (cellular)	lesional	GoF	transversion	-	-	-	transversion	-	prime editing	PMID35202617
HRAS	A59_Q61delinsGGSIL	c.176_182delinsGAGGATCCATACT	NM_005343.4	KLA (cellular)	lesional	GoF	indel	-	-	-	indel	-	prime editing / gene replacement	PMID35202617
HRAS	E63_S65delinsDIPP	c.189_195delinsCATCCCGCCG	NM_005343.4	KLA	0.54%	GoF	indel	-	-	-	indel	-	prime editing / gene replacement	PMC11184491
HRAS	M72_R73insHSAMRDQYM	c.191_217dup	NM_005343.4	GLA	0.51-0.63%	GoF	indel	-	-	-	indel	-	prime editing / gene replacement	PMC11184491
HRAS	M72_R73insHSAMRDQYM	c.191_217dup	NM_005343.4	CCLA	0.51-0.63%	GoF	indel	-	-	-	indel	-	prime editing / gene replacement	PMC11184491
KRAS	G12D	c.35G>A	NM_004985.5	CCLA	1.4-44%	GoF	transition	ABE	coding	NG	clean-BE	-	base editing (clean)	PMC10243805; PMC11184491
KRAS	G12D	c.35G>A	NM_004985.5	KLA	0.55%	GoF	transition	ABE	coding	NG	clean-BE	-	base editing (clean)	PMC11184491
KRAS	G12V	c.35G>T	NM_004985.5	GSD	23-28% (lesional tissue)	GoF	transversion	-	-	-	transversion	-	prime editing	PMC8410066
KRAS	G12V	c.35G>T	NM_004985.5	CCLA	0.77%	GoF	transversion	-	-	-	transversion	-	prime editing	PMC11184491
KRAS	G13D	c.38G>A	NM_004985.5	CCLA	10.3-38.8%	GoF	transition	ABE	coding	NG	clean-BE	-	base editing (clean)	PMC10243805
KRAS	A146T	c.436G>A	NM_004985.5	CCLA	3.3-3.9%	GoF	transition	ABE	coding	NGG	clean-BE	silent	base editing (clean)	PMC10243805; PMC11184491
KRAS	Q61R	c.182A>G	NM_004985.5	GSD	1%	GoF	transition	CBE	antisense	NG	BE-with-bystanders	silent;E62K	base editing (bystander)	PMID32591603
KRAS	Q70_Y71ins15	c.167_211dup	NM_004985.5	GLA	1.22%	GoF	indel	-	-	-	indel	-	prime editing / gene replacement	PMC11184491
BRAF	V600E	c.1799T>A	NM_004333.6	LM	0.1-3.6%	GoF	transversion	-	-	-	transversion	-	prime editing	PMC8972000
BRAF	V600E	c.1799T>A	NM_004333.6	GLA	0.2-8%	GoF	transversion	-	-	-	transversion	-	prime editing	PMC11184491; PMC12821086
BRAF	V600E	c.1799T>A	NM_004333.6	KLA	0.2-2.2%	GoF	transversion	-	-	-	transversion	-	prime editing	PMC12821086
BRAF	V600E	c.1799T>A	NM_004333.6	CCLA	0.21-2.6%	GoF	transversion	-	-	-	transversion	-	prime editing	PMC11184491; PMC12821086
ARAF	S214P	c.640T>C	NM_001654.5	CCLA	GoF	GoF	transition	CBE	coding	none	no-PAM	-	prime editing (no PAM)	PMID31263281
MAP2K1	F53C	c.158T>G	NM_002755.4	CCLA	0.8%	GoF	transversion	-	-	-	transversion	-	prime editing	PMC11184491
CBL	Y774*	c.2322T>G	NM_005188.4	KLA	4%	LoF	transversion	-	-	-	transversion	-	prime editing / gene replacement	PMC7539180